Atossa Therapeutics staples CVRs to shares tied to priority review voucher proceeds
ATOS•Atossa attached one contingent value right to each common share, entitling holders to 25% of net proceeds from the first qualifying FDA priority review voucher monetization, capped at $50 million.
1. CVR terms
The rights cover shares outstanding on the Oct. 19, 2026 record date, including shares issued before detachment or expiry. They transfer only with the related shares unless the board elects to detach them, and apply to the first qualifying voucher awarded on or before Dec. 31, 2036, subject to board extension.
